Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2006
10/19/2006WO2006109081A1 Dna-pk inhibitors
10/19/2006WO2006109075A2 Hydroxybenzamide derivatives and their use as inhibitors of hsp90
10/19/2006WO2006109069A1 Use of a metal ion chelating agent for the treatment of animal and human parasites
10/19/2006WO2006109058A1 New bicyclic angiotensin ii agonists
10/19/2006WO2006109056A1 New tricyclic angiotensin ii agonists
10/19/2006WO2006109048A1 New tricyclic angiotensin ii agonists
10/19/2006WO2006109026A1 4-(pyrid-2-yl) amino substituted pyrimidine as protein kinase inhibitors
10/19/2006WO2006108880A1 S-adenosyl-l-methionine for regulating behavioral disorders in pets
10/19/2006WO2006108842A1 Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
10/19/2006WO2006108837A1 Aminoalkyl-amidomethyl-substituted 2- (4-sulphonylamino) -3-hydroxy-3 , 4-dihydro-2h-cromen-6-yl derivatives and their use as potassium channel blockers
10/19/2006WO2006108828A1 (1, 10b-dihydro-2-(aminoalkyl- phenyl)-5h-pyraz0l0 [1,5-c] [1,3] benz0xazin-5-yl) phenyl methanone derivatives as hiv viral repliation inhibitors
10/19/2006WO2006108800A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
10/19/2006WO2006108789A1 Novel enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors
10/19/2006WO2006108773A1 (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
10/19/2006WO2006108763A1 Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
10/19/2006WO2006108719A1 Method of treating or preventing type-2 diabetes
10/19/2006WO2006108714A2 Tetrahydronaphthalene derivatives method for the production and the use thereof in the form of antiphlogistics
10/19/2006WO2006108712A1 Tetrahydronaphthalene derivatives method for the production and the use thereof in the form of antiphlogistics
10/19/2006WO2006108711A1 Substituted chroman derivatives, method for the production and the use thereof in the form of antiphlogistics
10/19/2006WO2006108709A1 3-sulfonylamino-pyrrolidine-2-one derivatives as factor xa inhibitors
10/19/2006WO2006108701A1 3- (1,2,4-triazol-3ylalkyl) azabriclo (3.1.0) hexane derivatives as modulators of dopamine d3 receptors
10/19/2006WO2006108700A1 3-triazolylthioalkyl-3-azabicyclo (3 - 1 - o) hexanes and their use as dopamine d3 receptor ligands
10/19/2006WO2006108699A1 Indazoles as glucocorticoid receptor ligands
10/19/2006WO2006108689A2 Process for preparing bicyclic compounds
10/19/2006WO2006108670A2 Use of cd25 antibodies in immunotherapy
10/19/2006WO2006108666A1 Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
10/19/2006WO2006108640A1 Phenylacetamides suitable as protein kinase inhibitors
10/19/2006WO2006108591A1 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
10/19/2006WO2006108572A2 Novel crystalline pharmaceutical product
10/19/2006WO2006108565A1 Spirocyclic cyclohexane derivatives for use in the treatment of substance dependency
10/19/2006WO2006108561A1 A process for the purification of 10-deacetylbaccatine iii from 10-de acet yl-2- debenzoyl-2-pentenoylbaccatine iii
10/19/2006WO2006108519A1 Therapeutic combination in case of benign prostate hyperplasia
10/19/2006WO2006108506A1 Uses of 2-phenyl-substituted imidazotriazinone derivatives for treating pulmonary hypertension
10/19/2006WO2006108489A1 Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
10/19/2006WO2006108488A1 Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
10/19/2006WO2006108482A1 Purine derivatives as receptor-tyrosine kinase activityinhibitors
10/19/2006WO2006108429A1 Nutrient composition for treating sarcoma and prostate cancer
10/19/2006WO2006108428A1 A process for the preparation of an oxaliplatin preparation
10/19/2006WO2006108424A2 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
10/19/2006WO2006108358A1 ANTIVIRAL USE OF ARTIFICIAL CpG-CONTAINING SINGLE-STRANDED OLIGODEOXYNUCLEOTIDES IN COMBINATION WITH RIBAVIRIN
10/19/2006WO2006108354A1 1-(substituted phenyl)-5- methyl- 2 - (1h) pyridone in the manufacture of medicaments for treating fibrosis in organs or tissues
10/19/2006WO2006108295A1 Supplemental dietary composition for increasing muscle size and strength
10/19/2006WO2006108283A1 Dietary fiber composition comprising glucomannan, xanthan gum, and alginate
10/19/2006WO2006108276A1 A method of treating cancer using dichloroacetate
10/19/2006WO2006108239A1 Ocular drug delivery
10/19/2006WO2006108225A1 Method of screening for compounds that modulate cell proliferation
10/19/2006WO2006108224A1 Antiparasitic compounds
10/19/2006WO2006108212A1 Anti-inflammatory modalities
10/19/2006WO2006096810A3 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0] hexanes
10/19/2006WO2006093401A3 Liquid non-flammable gas mixture and a container and package therefor
10/19/2006WO2006092151A8 Topical corticosteroid containing formulation for treatment of psoriasis, eczema, ulcer and burns
10/19/2006WO2006089312A3 Orally bioavailable cci-779 tablet formulations
10/19/2006WO2006087577A3 Inhibition or treatment of dyskinesia
10/19/2006WO2006085895A3 Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
10/19/2006WO2006085212A3 Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv
10/19/2006WO2006085208A3 Stable solid dosage forms of amlodipine and benazepril
10/19/2006WO2006085118A3 Dihydroimidazothiazole derivatives
10/19/2006WO2006083979A3 Local treatment of neurofibromas
10/19/2006WO2006083841A3 Therapeutic esters
10/19/2006WO2006082598A3 Novel crystalline forms of rizatriptan benzoate
10/19/2006WO2006082428A3 Combination therapies using hdac inhibitors
10/19/2006WO2006081562A3 Synthesis of aryl pyrrolidones
10/19/2006WO2006081178A3 Antibacterial agents
10/19/2006WO2006078277A3 Dalbavancin compositions for treatment of bacterial infections
10/19/2006WO2006076240A3 Compositions, products and methods for controlling weight in a mammal
10/19/2006WO2006074218A3 Nanoparticulate candesartan formulations
10/19/2006WO2006074094A3 Method for producing probiotically derived compounds
10/19/2006WO2006071897A3 Treatment of macular degeneration with lonidamine
10/19/2006WO2006071471A3 2-(2 or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
10/19/2006WO2006069395A3 Synthetic process for the preparation of biocyclic compounds
10/19/2006WO2006068932A3 Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
10/19/2006WO2006066937A3 Mnk1 or mnk2 inhibitors
10/19/2006WO2006065601A8 Inhibitors of akt activity
10/19/2006WO2006064336A3 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
10/19/2006WO2006063350A3 Compositions and methods for treating conditions of the nail unit
10/19/2006WO2006060649A3 Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease
10/19/2006WO2006060618A3 Topical nepafenac formulations
10/19/2006WO2006053323B1 Inhibitors of hiv-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof
10/19/2006WO2006053201A3 Treatment of cancer by simultaneous inhibition of b-raf and restoration or mimicry of p16 ink4a activity
10/19/2006WO2006053082A3 Hydroxybenzoate salts of metanicotine compounds
10/19/2006WO2006052461A3 Novel formulations of eprosartan with enhanced bioavailability
10/19/2006WO2006050476A3 Pyrimidine derivatives as ion channel modulators and methods of use
10/19/2006WO2006050447A3 Apogossypolone and the uses thereof
10/19/2006WO2006050303A3 Intravaginal treatment of vaginal infections with metronidazole compositions
10/19/2006WO2006050026A3 Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
10/19/2006WO2006050006A3 ((1h-indazol-3-yl)methyl) phenols and (hydroxyphenyl)(1h-indazol-3-yl) methanones as ligands of the estrogen receptor
10/19/2006WO2006049984A3 Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
10/19/2006WO2006045616A3 β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
10/19/2006WO2006044335A3 Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer
10/19/2006WO2006044107A3 Method of treating human preeclampsia employing resibufagenin
10/19/2006WO2006039691A3 Morphine and morphine precursors
10/19/2006WO2006039250A3 Chemokine-binding heterocyclic compound salts, and methods of use thereof
10/19/2006WO2006037482A3 Compositions and methods for treating cognitive disorders
10/19/2006WO2006036936A3 The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
10/19/2006WO2006036892A3 Use of inhibitors of 24-hydroxylase in the treatment of cancer
10/19/2006WO2006035204A3 Combination comprising zd6474 and an imatinib
10/19/2006WO2006032042A3 Us of cntf or a cntf derivative in combination with a further compound for the preparation of medicament for the treatment of obesity
10/19/2006WO2006029893A3 Composition for inhibiting or preventing the formation of a biofilm
10/19/2006WO2006023791A3 Methods and compositions for treating allergic inflammation
10/19/2006WO2006023603A3 Pde5 inhibitor compositions and methods for treating cardiac indications
1 ... 4042 4043 4044 4045 4046 4047 4048 4049 4050 4051 4052 4053 4054 4055 4056 4057 4058 4059 4060 4061 4062 ... 7860